Neuraptive Receives FDA Breakthrough Designation for NTX-001 and Updates on Peripheral Nerve Injury Treatment
Neuraptive Therapeutics, Inc. has announced that its therapy NTX-001 has received Breakthrough Therapy Designation from the FDA, which could accelerate its development for patients with peripheral nerve injuries that need repair. This designation is based on promising results from the…
ŌURA Acquires Veri to Enhance Metabolic Health Capabilities
ŌURA, the company behind the Oura Ring, has announced its acquisition of Veri, a Finnish firm specializing in personalized metabolic health. Veri, which partners with Oura to offer metabolic insights through continuous glucose monitors (CGMs), will see a significant portion…
Viridian Therapeutics Prices Upsized Public Offering of Common and Preferred Stock
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotech firm specializing in developing treatments for rare and serious diseases, has announced the pricing of its public offering. The company will sell 10,666,600 shares of common stock at $18.75 each and 20,000 shares…
Spencer Health Solutions Earns ISO 27001 Certification
Spencer Health Solutions (SHS), a leader in intelligent medication management technology, has announced its achievement of ISO 27001:2022 certification. This esteemed accreditation highlights SHS’s dedication to safeguarding patient data and maintaining top-tier information security standards. ISO 27001 is a globally…
Signet Healthcare Sells Paragonix Technologies to Getinge
Signet Healthcare Partners (“Signet”) has announced the successful sale of its portfolio company, Paragonix Technologies (“Paragonix”), to global medical technology leader Getinge. Paragonix, renowned for its advancements in organ transplantation and preservation, marks a significant acquisition for Getinge, enhancing its…
Contraline & Population Council Strike Deal for Innovative Male Contraceptive
Contraline, Inc., a clinical-stage biotechnology firm, has signed an exclusive option-to-license agreement with the Population Council for the Nestorone/Testosterone Transdermal Gel (NES/T) for male contraception. If the option is exercised, Contraline will lead the global development and commercialization of NES/T,…
Vaxxas Launches Phase I Trial of H7N9 Vaccine with HD-MAP Technology
Vaxxas announced the start of a multi-center Phase I clinical trial for a vaccine targeting the pre-pandemic avian influenza strain H7N9, using its high-density microarray patch (HD-MAP) technology. Vaxxas has initiated a multi-center Phase I clinical trial of a pre-pandemic…
EORTC Expands Partnership with Medidata for Next Phase of Cancer Research
Medidata, a Dassault Systèmes brand and leader in clinical trial solutions for the life sciences industry, has announced a four-year extension of its partnership with the European Organisation for Research and Treatment of Cancer (EORTC). This extension aims to enhance…
Cellworks Biosimulation Pinpoints NSCLC Patients for Chemo-Immunotherapy Combo
Cellworks Group Inc., a leader in personalized therapy decision support and precision drug development, recently announced the results of a study demonstrating the accuracy of its biosimulation platform in predicting overall survival (OS) and chemotherapy benefits in two real-world cohorts…
New Breast Density Reporting Law Empowers Women; Komen Calls for Affordable Care Access
Susan G. Komen®, the leading breast cancer organization, today applauds the new U.S. Food and Drug Administration (FDA) rule requiring mammography reports to include details about breast density. This federal mandate standardizes notification language, ensuring that all individuals across the…
HDS Unveils Script Scan: New Analytics Platform for Pharmacy Performance and Profitability
HDS has launched Script Scan, a new addition to its Spotlight platform. This is the company’s first product specifically designed for pharmacies. Script Scan addresses the current challenges faced by pharmacy operators, including shrinking margins, limited staff, and intense market…
Inflammasome Therapeutics Completes Enrollment in Dual Inflammasome Inhibitor Study
Inflammasome Therapeutics, a private company, has finished enrolling participants in a Phase I pharmacokinetics and safety study for its novel drug K9. This brain- and retina-penetrant compound is being evaluated for its potential in treating various neuroinflammatory and degenerative diseases,…